Sequel Pharmaceuticals (India) Private Limited

Sequel Pharmaceuticals (India) Private Limited - pharma in Ambernath, Maharashtra, India. FY 2026 financials and compliance.
CIN U24239MH2006PTC162896 Incorporated 28 June 2006 ROC Mumbai HQ Ambernath, Maharashtra, India
Active Private Limited Company pharma
Data last updated
Revenue · FY 2023
-
Latest filing
EBITDA · FY 2023
*****
▲ 95.80% YoY
Net profit · FY 2023
*****
▲ 95.55% YoY
Authorised capital
₹6 Cr
Registered with MCA
Paid-up capital
₹5.8 Cr
Issued & subscribed
Open charges
₹5 Cr
Satisfied ₹36.09 Cr
Company age
20 yrs
Est. 2006
Last financials
Mar 2024
Balance sheet date

About Sequel Pharmaceuticals (India) Private Limited

Data last updated: 22 December 2025

Sequel Pharmaceuticals (India) Private Limited is a private limited company based in Ambernath, Maharashtra, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 28 June 2006, the company has been in operation for over 20 years.

Registered with ROC Mumbai under CIN U24239MH2006PTC162896.

Capital: an authorised share capital of ₹6 Cr and a paid-up capital of ₹5.8 Cr. Formerly known as Sequel Pharmachem Private Limited and Sequel Pharmaceuticals Private Limited. It is led by directors Ramchandra Haridas Parade and Nandadip Sakharam Rasam.

Last AGM: 30 September 2024. Financial statements filed for year ended 31 March 2024. Office: N – 46 Ambernath Midc Anand Nagar, Maharashtra, India – 421504.

As per MCA filings, the company has open charges of ₹5 Cr and satisfied charges of ₹36.09 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies.

Company Details of Sequel Pharmaceuticals (India) Private Limited
CIN U24239MH2006PTC162896
Registration Number 162896
Incorporation Date 28 June 2006
ROC Mumbai
Listing Status Unlisted
Company Status Active
Date of Last AGM 30 September 2024
Date of Balance Sheet 31 March 2024
Compliance Status Active Compliant
Key People
Ramchandra Haridas Parade Director Nandadip Sakharam Rasam Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    **************
  • Social Media
    **************
  • Registered Address
    N – 46 Ambernath Midc Anand Nagar, Maharashtra, India – 421504
  • Industry
    Pharma, Drug Formulation & Development
Company report
Sequel Pharmaceuticals (India) Private Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Sequel Pharmaceuticals (India) Private Limited report

Financials, compliance, directors, charges, ownership and filings for Sequel Pharmaceuticals (India) Private Limited in one report.

10-year financials Directors & ownership Charges & compliance

Name History of Sequel Pharmaceuticals (India) Private Limited

Sequel Pharmaceuticals (India) Private Limited has undergone 2 name changes throughout its history. The company was previously known as Sequel Pharmachem Private Limited, and Sequel Pharmaceuticals Private Limited. The current legal name is Sequel Pharmaceuticals (India) Private Limited, reflecting the company's evolution and rebranding over time.

Company Name Status
Sequel Pharmaceuticals (India) Private Limited Current
Sequel Pharmachem Private Limited Previous
Sequel Pharmaceuticals Private Limited Previous

Auditor Details of Sequel Pharmaceuticals (India) Private Limited

Sequel Pharmaceuticals (India) Private Limited is audited by Prakash Ravatale & Associates for the financial year 2023. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.

Name Status Appointment Date Cessation Date
Prakash Ravatale & Associates blur-value blur-value blur-value

Board of Directors of Sequel Pharmaceuticals (India) Private Limited

Sequel Pharmaceuticals (India) Private Limited is currently managed by 2 directors, with 6 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Ramchandra Haridas Parade Director 18 Jun 2020 6 Years 0 Months Current
Nandadip Sakharam Rasam Director 06 May 2023 3 Years 2 Months Current
View all directors

Financials of Sequel Pharmaceuticals (India) Private Limited FY 2024 filings available

Sequel Pharmaceuticals (India) Private Limited reported revenue of ₹- (up ) for FY 2023. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue
-
Profit
***** ▲ 95.55%
EBITDA
***** ▲ 95.80%
Metrics
*****
*****
*****
*****
*****
Revenue
Revenue from Operations
*****
*****
*****
*****
*****
Revenue Growth %
*****
*****
*****
*****
*****
Other Income
*****
*****
*****
*****
*****
Total Revenue
*****
*****
*****
*****
*****
Expenses
Total Expenses
*****
*****
*****
*****
*****
Raw Material Cost
*****
*****
*****
*****
*****
Change in Inventory FG
*****
*****
*****
*****
*****
Change in Inventory WIP
*****
*****
*****
*****
*****
Purchase of Traded Goods
*****
*****
*****
*****
*****
Employee Cost
*****
*****
*****
*****
*****
Managerial Remuneration
*****
*****
*****
*****
*****
Audit Fees
*****
*****
*****
*****
*****
Insurance
*****
*****
*****
*****
*****
Power & Fuel
*****
*****
*****
*****
*****
Interest
*****
*****
*****
*****
*****
Depreciation
*****
*****
*****
*****
*****
Other Expenses
*****
*****
*****
*****
*****
Profitability
EBITDA (Operating Profit)
*****
*****
*****
*****
*****
Operating Margin %
*****
*****
*****
*****
*****
Exceptional Items
*****
*****
*****
*****
*****
Extraordinary Items
*****
*****
*****
*****
*****
Profit Before Exceptional & Extraordinary Items
*****
*****
*****
*****
*****
Profit Before Tax
*****
*****
*****
*****
*****
Tax & Net Profit
Tax Expense
*****
*****
*****
*****
*****
Current Tax
*****
*****
*****
*****
*****
Deferred Tax
*****
*****
*****
*****
*****
Profit from Discontinued Operations
*****
*****
*****
*****
*****
Tax on Discontinued Operations
*****
*****
*****
*****
*****
Profit
*****
*****
*****
*****
*****
Net Margin %
*****
*****
*****
*****
*****
Metrics
*****
*****
*****
*****
*****
Shareholders' Funds
Total Shareholders' Funds
*****
*****
*****
*****
*****
Equity Capital
*****
*****
*****
*****
*****
Reserves & Surplus
*****
*****
*****
*****
*****
Money Against Warrants
*****
*****
*****
*****
*****
Other Equity
*****
*****
*****
*****
*****
Non-Current Liabilities
Total Non-Current Liabilities
*****
*****
*****
*****
*****
Long-Term Borrowings
*****
*****
*****
*****
*****
Deferred Tax Liabilities
*****
*****
*****
*****
*****
Other Non-Current Liabilities
*****
*****
*****
*****
*****
Long-Term Provisions
*****
*****
*****
*****
*****
Current Liabilities
Total Current Liabilities
*****
*****
*****
*****
*****
Short-Term Borrowings
*****
*****
*****
*****
*****
Trade Payables
*****
*****
*****
*****
*****
Other Current Liabilities
*****
*****
*****
*****
*****
Short-Term Provisions
*****
*****
*****
*****
*****
Total Equity & Liabilities
*****
*****
*****
*****
*****
Non-Current Assets
Non-Current Assets
*****
*****
*****
*****
*****
Tangible Assets
*****
*****
*****
*****
*****
Intangible Assets
*****
*****
*****
*****
*****
Capital WIP
*****
*****
*****
*****
*****
Intangibles Under Dev
*****
*****
*****
*****
*****
Investments
*****
*****
*****
*****
*****
Deferred Tax Assets
*****
*****
*****
*****
*****
LT Loans & Advances
*****
*****
*****
*****
*****
Other Non-Current Assets
*****
*****
*****
*****
*****
Current Assets
Current Assets
*****
*****
*****
*****
*****
Current Investments
*****
*****
*****
*****
*****
Inventories
*****
*****
*****
*****
*****
Trade Receivables
*****
*****
*****
*****
*****
Cash & Bank Balance
*****
*****
*****
*****
*****
ST Loans & Advances
*****
*****
*****
*****
*****
Other Current Assets
*****
*****
*****
*****
*****
Total Assets
*****
*****
*****
*****
*****
Metrics
*****
*****
*****
*****
*****
Cash from Operating Activities (CFO)
Profit Before Tax
*****
*****
*****
*****
*****
Non-Cash Adjustments
*****
*****
*****
*****
*****
+ Interest Expense
*****
*****
*****
*****
*****
+ Depreciation
*****
*****
*****
*****
*****
+/- Unrealized Forex
*****
*****
*****
*****
*****
- Dividend Income
*****
*****
*****
*****
*****
- Interest Income
*****
*****
*****
*****
*****
+/- Other Non-Cash Items
*****
*****
*****
*****
*****
Changes in Working Capital
*****
*****
*****
*****
*****
+/- Inventory
*****
*****
*****
*****
*****
+/- Debtors
*****
*****
*****
*****
*****
+/- Creditors
*****
*****
*****
*****
*****
Reconciliation Adjustments
*****
*****
*****
*****
*****
Cash Generated from Operations
*****
*****
*****
*****
*****
Income Taxes Paid
*****
*****
*****
*****
*****
Net CFO (Cash from Operations)
*****
*****
*****
*****
*****
Cash from Investing Activities (CFI)
Acquisitions & Disposals
*****
*****
*****
*****
*****
Disposal of Subsidiaries
*****
*****
*****
*****
*****
Acquisition of Subsidiaries
*****
*****
*****
*****
*****
Capex
*****
*****
*****
*****
*****
Purchase of Fixed Assets
*****
*****
*****
*****
*****
Sale of Fixed Assets
*****
*****
*****
*****
*****
Other Investing Cash Flows
*****
*****
*****
*****
*****
Net CFI (Cash from Investing)
*****
*****
*****
*****
*****
Cash from Financing Activities (CFF)
Equity Issuance
*****
*****
*****
*****
*****
Debt Raised
*****
*****
*****
*****
*****
Debt Repaid
*****
*****
*****
*****
*****
Dividends Paid
*****
*****
*****
*****
*****
Interest Paid
*****
*****
*****
*****
*****
Net CFF (Cash from Financing)
*****
*****
*****
*****
*****
Net Cash Position
Net Change in Cash (Pre-Forex)
*****
*****
*****
*****
*****
Closing Cash & Equivalents
*****
*****
*****
*****
*****
Metrics
*****
*****
*****
*****
*****
Liquidity
Current Ratio
*****
*****
*****
*****
*****
Quick Ratio
*****
*****
*****
*****
*****
Cash Ratio
*****
*****
*****
*****
*****
Efficiency
Inventory Days
*****
*****
*****
*****
*****
Debtor Days
*****
*****
*****
*****
*****
Creditor Days
*****
*****
*****
*****
*****
Cash Conversion Cycle
*****
*****
*****
*****
*****
Asset Turnover
*****
*****
*****
*****
*****
Profitability
Net Profit Margin %
*****
*****
*****
*****
*****
Operating Margin %
*****
*****
*****
*****
*****
ROE %
*****
*****
*****
*****
*****
ROCE %
*****
*****
*****
*****
*****
Net Worth Margin %
*****
*****
*****
*****
*****
Growth
Revenue Growth %
*****
*****
*****
*****
*****
Leverage
Equity Multiplier
*****
*****
*****
*****
*****
Debt / EBITDA
*****
*****
*****
*****
*****
Solvency
D/E Ratio
*****
*****
*****
*****
*****
ICR
*****
*****
*****
*****
*****

Consolidated Statements

Income Statement, Balance Sheet, Cash Flow & Ratios available in the full report.

Unlock Complete Financial History (FY 2015 – Latest)
Standalone & Consolidated - Income Statement, Balance Sheet, Cash Flow, Financial Ratios and Growth Trends with 10+ years of line-item data.
10+ years of data Line-item breakdown Balance Sheet detail Cash Flow analysis 20+ ratios & metrics Downloadable PDF

Shareholding Pattern of Sequel Pharmaceuticals (India) Private Limited

As of FY 2023, Sequel Pharmaceuticals (India) Private Limited's shareholding pattern shows 100.00% by promoters. The promoters hold a majority stake, indicating strong promoter control.

2025
YEAR
38.19% Promoters
25.22% DII (Domestic Institutional)
10.28% FII (Foreign Institutional)
25.89% Public
2.42% Others
Shareholding Trend
Year 2025
Promoters 33.19%
DII 23.22%
FII 18.28%
Public 22.89%
Others 2.42%

Charges & Borrowings of Sequel Pharmaceuticals (India) Private Limited

Open charges
₹5 Cr
Satisfied charges
₹36.09 Cr
Breakdown by lending institutions
Nkgsb Co-Op. Bank Ltd.₹5.00 Cr
Latest charge details
DateLenderAmountStatus
07 Apr 2011 Nkgsb Co-Op. Bank Ltd. ₹5 Cr Open
22 Dec 2007 Corporation Bank ₹29.31 Cr Satisfied
10 Aug 2007 Janakalyan Sahakari Bank Ltd. ₹4.18 Cr Satisfied
12 Apr 2007 Janakalyan Sahakari Bank Limited ₹1.6 Cr Satisfied
12 Apr 2007 Janakalyan Sahakari Bank Ltd. ₹1 Cr Satisfied

Total charge records: 5 View all charges

Employees and EPFO Compliance at Sequel Pharmaceuticals (India) Private Limited

View historical data on people associated with Sequel Pharmaceuticals (India) Private Limited, including employment history and EPFO contributions.

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Sequel Pharmaceuticals (India) Private Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Sequel Pharmaceuticals (India) Private Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Sequel Pharmaceuticals (India) Private Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Sequel Pharmaceuticals (India) Private Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Sequel Pharmaceuticals (India) Private Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Sequel Pharmaceuticals (India) Private Limited

MSME Payment Delays by Sequel Pharmaceuticals (India) Private Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Sequel Pharmaceuticals (India) Private Limited

Subsidiaries & Group Companies of Sequel Pharmaceuticals (India) Private Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Sequel Pharmaceuticals (India) Private Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Sequel Pharmaceuticals (India) Private Limited

MCA Filings & Documents of Sequel Pharmaceuticals (India) Private Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Sequel Pharmaceuticals (India) Private Limited

Activity
30 Sep 2024
Sequel Pharmaceuticals (India) Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Activity
31 Mar 2024
Sequel Pharmaceuticals (India) Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Mumbai.
Directors
06 May 2023
Nandadip Sakharam Rasam was appointed as a Director on 06 May 2023 & has been associated with this company since 3 years 2 months.
Directors
18 Jun 2020
Ramchandra Haridas Parade was appointed as a Director on 18 Jun 2020 & has been associated with this company since 6 years 22 days.
Charges
07 Jun 2017
A charge registered on 10 Aug 2007 via Charge ID 10063597 with Janakalyan Sahakari Bank Ltd. was fully satisfied on 07 Jun 2017.
Charges
07 Jun 2017
A charge registered on 12 Apr 2007 via Charge ID 10096643 with Janakalyan Sahakari Bank Limited was fully satisfied on 07 Jun 2017.

Frequently Asked Questions about Sequel Pharmaceuticals (India) Private Limited

Sequel Pharmaceuticals (India) Private Limited is an active private limited company in the pharma sector based in Ambernath, Maharashtra, India. It was incorporated on 28 June 2006 (20+ years old) and is registered under CIN U24239MH2006PTC162896.

The current directors of Sequel Pharmaceuticals (India) Private Limited are:

The primary industry of Sequel Pharmaceuticals (India) Private Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Sequel Pharmaceuticals (India) Private Limited can be reached at the registered office: N – 46 Ambernath Midc Anand Nagar, Maharashtra, India – 421504.

The authorised capital is ₹6 Cr, and the paid-up capital is ₹5.8 Cr.

The company has its registered office at N – 46 Ambernath Midc Anand Nagar, Maharashtra, India – 421504.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available